PMID- 27293826 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160613 LR - 20220318 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 8 IP - 6 DP - 2016 Jun TI - High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma. PG - 1103-11 LID - 10.21037/jtd.2016.03.96 [doi] AB - BACKGROUND: Lung cancer has heterogeneous features. It remains unclear whether ALK rearrangement was distributed heterogeneously in tumor from different anatomic sites. To address this issue, we investigate the concordance of ALK rearrangement between primary tumors and paired metastatic lymph nodes in pulmonary adenocarcinoma patients. METHODS: From Sep 2013 to May 2014, resectable lung adenocarcinoma patients with EGFR wildtype and paired metastatic lymph nodes from Tongji University affiliated Shanghai pulmonary hospital were selected into this study. An auto-mated Ventana ALK with clone D5F3 antibody immunohistochemistry (IHC) and reverse transcriptase-polymerase chain reaction (RT-PCR) were used to detected ALK rearrangement. Discordant cases between IHC and RT-PCR were further validated by fluorescence in situ hybridization (FISH). RESULTS: A total of 101 patients were enrolled into this study with a median age of 60 years old (range, 35-78 years). ALK rearrangement was found in 20 primary lesions, while in 18 paired metastatic lymph nodes. ALK rearrangement was more frequently happened in younger (P<0.001), Nonsmokers (P=0.012), high-stage disease (P=0.021) and predominantly solid growth pattern (P=0.024). The concordance rate between primary tumor and paired metastatic lymph nodes was 98%. Two patients with ALK rearrangement on primary tumor didn't show ALK gene fusion on paired metastatic lymph nodes. Sixty-eight cases had more than two stations of metastatic lymph nodes. ALK rearrangement in the different station of metastatic lymph nodes of the same patient was consistent. CONCLUSIONS: High concordant rate of ALK rearrangement between primary tumors and paired metastatic lymph nodes were found in this study. The authors concluded that specimens from metastatic lesions and primary tumors are equally suitable for detection ALK rearrangement. FAU - Hou, Likun AU - Hou L AD - 1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Ren, Shengxiang AU - Ren S AD - 1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Su, Bo AU - Su B AD - 1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Zhang, Liping AU - Zhang L AD - 1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Wu, Wei AU - Wu W AD - 1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Zhang, Wei AU - Zhang W AD - 1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Dong, Zhengwei AU - Dong Z AD - 1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Huang, Yan AU - Huang Y AD - 1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Wu, Chunyan AU - Wu C AD - 1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Chen, Gang AU - Chen G AD - 1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. LA - eng PT - Journal Article PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC4885982 OTO - NOTNLM OT - ALK rearrangement OT - fluorescence in situ hybridization (FISH) OT - heterogeneity OT - immunohistochemistry (IHC) OT - lung adenocarcinoma OT - reverse transcriptase-polymerase chain reaction (RT-PCR) COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2016/06/14 06:00 MHDA- 2016/06/14 06:01 PMCR- 2016/06/01 CRDT- 2016/06/14 06:00 PHST- 2016/06/14 06:00 [entrez] PHST- 2016/06/14 06:00 [pubmed] PHST- 2016/06/14 06:01 [medline] PHST- 2016/06/01 00:00 [pmc-release] AID - jtd-08-06-1103 [pii] AID - 10.21037/jtd.2016.03.96 [doi] PST - ppublish SO - J Thorac Dis. 2016 Jun;8(6):1103-11. doi: 10.21037/jtd.2016.03.96.